Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels

被引:30
作者
Aleksa, K
Ito, S
Koren, G
机构
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON, Canada
来源
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 2004年 / 143卷 / 03期
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.lab.2003.10.013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
lfosfamide (IF) improves survival in children with solid tumors but causes a high rate of. nephrotoxicity. We hypothesized that this is caused by an oxidative metabolite of IF, chloroacetaldehyde, which is produced locally by the cells of the renal tubule (RT). For this hypothesis to be viable, one must document that chloroacetaldehyde concentrations in the RT cell are consistent with levels shown to cause nephrotoxicity in experimental systems. Using pharmacokinetic modeling of experimental data, we show that the median level of chloroacetaldehyde in RT cells is 80 mumol/L, ranging from 35 to 320 mumol/L. These concentrations are consistent with levels shown experimentally to cause functional and structural RT damage and lends validity to the hypothesis that local renal production of chloroacetaldehyde causes nephrotoxicity.
引用
收藏
页码:159 / 162
页数:4
相关论文
共 16 条
[1]
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report [J].
Abu-Ghosh, AM ;
Krailo, MD ;
Goldman, SC ;
Slack, RS ;
Davenport, V ;
Morris, E ;
Laver, JH ;
Reaman, GH ;
Cairo, MS .
ANNALS OF ONCOLOGY, 2002, 13 (03) :460-469
[2]
Developmental renal tubular toxicity: A hypothetical framework and experimental approaches [J].
Aleksa, K ;
Ito, S ;
Koren, G .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (12) :930-941
[3]
Dubourg L, 2001, J AM SOC NEPHROL, V12, P1615, DOI 10.1681/ASN.V1281615
[4]
KUNG FH, 1993, CANCER-AM CANCER SOC, V71, P1898, DOI 10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO
[5]
2-Q
[6]
Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas [J].
Marina, NM ;
Poquette, CA ;
Cain, AM ;
Jones, D ;
Pratt, CB ;
Meyer, WH .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (02) :112-118
[7]
IFOSFAMIDE ENANTIOMERS - PHARMACOKINETICS IN CHILDREN [J].
PRASAD, VK ;
CORLETT, SA ;
ABAASI, K ;
HENEY, D ;
LEWIS, I ;
CHRYSTYN, H .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (05) :447-449
[8]
PRATT CB, 1990, SEMIN ONCOL, V17, P31
[9]
PRATT CB, 1989, SEMIN ONCOL, V16, P51
[10]
PRATT CB, 1993, CANCER-AM CANCER SOC, V71, P3661, DOI 10.1002/1097-0142(19930601)71:11<3661::AID-CNCR2820711131>3.0.CO